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 Abstract: This study investigates the response of the
underlying sleep disorder associated with Chronic Fatigue
Syndrome (CFS) and fibromyalgia (FM) to treatment. We ret-
rospectively reviewed 118 cases clinically consistent with CFS
or FM, treated in a neurology practice. Abnormal findings
on sleep studies and associated human leukocyte antigen
markers, and a clinical pattern suggestive of narcolepsy, are
present in a high proportion of patients. When considered
appropriate based on the clinical picture and test results,
treatment with sodium oxybate was offered to these
patients. Sixty percent of patients treated with oxybate expe-
rienced significant relief of pain, while 75% experienced
significant relief of fatigue. We postulate that the response
to oxybate in CFS and FM suggests a disturbance of sleep
similar to narcolepsy. These findings support this novel
approach to intervention and further research. The inability
to distinguish CFS and FM by testing and response to treat-
ment suggests that they may represent variations of the
same disorder or may be closely related disorders. 
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INTRODUCTION
Treatment for fibromyalgia (FM) and Chronic Fatigue
Syndrome (CFS) have largely been unsatisfactory.
Recently, pregabalin and duloxetine have received
approval for FM, but in practice, relief for patients has
generally been limited. Because an underlying mecha-
nism in these disorders is not known, treatment has
been empiric. Treatment trials have focused on FM and
pain.
The descriptions and definitions of these disorders
have substantial overlap,1,2 and there is controversy
about the distinction between them. It is difficult to
clearly or objectively identify any abnormality in
patients carrying clinical diagnoses of CFS or FM.
Various mechanisms have been proposed, including
viral infections, immunological causes, dysfunction
of the hypothalamic-pituitary-adrenal axis, neurally-
mediated hypotension, and nutritional deficiencies3,4 but
despite extensive research, no exact mechanism has been
proven, nor has treatment aimed at these mechanisms
proven successful. The pathophysiology of CFS and
FM are therefore as yet considered unknown, and these
disorders are characterized as relatively refractory to
treatment.
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Traditionally, treatment for classical narcolepsy con-
sisted of daytime stimulant medication. However, more
recent recognition of the importance of hypocretin and
the disrupted sleep pattern these patients suffer has
resulted in another option for therapy. Treatment now
focuses on improving sleep, and in particular restor-
ative, deep sleep. Sodium oxybate has been approved
for narcolepsy and found to be quite effective, acting
through a mechanism of increased stage 3 and 4 deep
sleep.5–9 Conceptually, this approach to treatment is dia-
metrically opposed to previous methods using stimu-
lants, and recent treatment recommendations have
included oxybate as primary therapy.
Based on concepts of disrupted nocturnal sleep, some
patients with FM have been treated with oxybate. Cur-
rently published data show initial promising results,10,11
but the number of patients treated has been small and
the follow-up period has been short. These studies have
not included Multiple Sleep Latency Test (MSLT) and
human leukocyte antigen (HLA) data. No trial of
oxybate has been conducted in CFS as compared with
FM. Larger trials in FM, including double-blind placebo
controlled studies, are in progress.
This study was undertaken in a general neurology
practice and reports the results of treatment in a series
of patients with clinical features of CFS and FM. Many
of these patients had characteristics diagnostic of nar-
colepsy. We propose to classify these patients as a nar-
coleptiform syndrome. The results of clinical evaluation,
diagnostic testing, and classification of the narcoleptic
features in these patients provided a rationale for treat-
ment with sodium oxybate.
METHODS
This retrospective study was approved by the University
of Michigan Institutional Review Board. Subjects were
identified from a single practitioner, general neurology
practice originally referred for a range of diagnoses.
Many cases were referred for consideration of neuro-
muscular disorders, because of complaints of weakness
and myalgia. None of the cases were originally referred
for a primary sleep disorder. Only a minority were origi-
nally referred for a diagnosis of CFS (3/118, 2%) or FM
(33/118, 28%). In some cases, symptoms of CFS or FM
were discovered during the review of systems while a
patient was being treated for an unrelated disorder.
All cases referred to initiate oxybate over a 5-year
period (2003–2008) were identified from the federally
mandated registry. Charts that were incomplete at the
cutoff date, or that have been treated subsequently, were
not included. All diagnoses were made and all treat-
ments were rendered prior to the retrospective analysis,
and therefore patient selection, diagnosis, and treatment
were not influenced by the study. In the normal course
of practice, standard symptom questionnaires had not
been employed during treatment, and diagnoses were
clinical. Nonetheless, the clinical diagnostic criteria used
to establish diagnoses of FM and CFS followed estab-
lished published guidelines for these disorders (http://
www.cdc.gov/cfs/cfsdiagnosisHCP.htm).
Sleep studies were recommended in the course of
routine care to all patients in the practice clinically
identified with extreme fatigue, disrupted sleep, or
sleepiness. These included patients who presented
with generalized pain and also had fatigue. Nearly all
patients in the practice with severe fatigue did accept
recommendations for the sleep studies and had treat-
ment recommended. In many cases, HLA markers asso-
ciated with narcolepsy were also obtained. Because
patients found to have other causes of long-standing
fatigue were excluded, all patients remaining met clini-
cal criteria for either CFS or FM.
All patients who had oxybate recommended and
were referred to the registry over a 5-year period,
and whose records were complete for analysis, were
included in this study, even if they subsequently never
took the medication. This included patients who were
determined to meet criteria for treatment by combined
clinical and sleep study criteria, but a small percentage
of these were treated based on clinical criteria alone. A
patient was referred for treatment with sodium oxybate
if the clinical scenario was either classical or suggestive
of narcolepsy, although narcolepsy was not suspected
initially in any of these cases.
Patients underwent polysomnography (PSG) and
MSLT according to standard methodology. Patients
who had been recently started on new medications had
these discontinued before sleep studies were performed.
However, if a patient had been on medications for a
prolonged period of time, generally 6 months or greater,
no change was made in the regimen. Markers for HLA
DQB1-0602 were obtained. Any patients with another
cause of hypersomnia such as a restricted sleep schedule,
or a cause identified by PSG, such as Obstructive Sleep
Apnea or Restless Legs Syndrome, were excluded from
the study.
In making the diagnosis of narcolepsy, standard clini-
cal criteria were employed. No single factor, including
an isolated finding of rapid eye movement (REM) onset
or an HLA marker, was used to make the diagnosis
Narcoleptiform Sleep in Chronic Fatigue and Fibromyalgia • 55
of narcolepsy. Symptoms such as excessive sleepiness,
cataplexy and sleep paralysis, MSLT results, Sleep Onset
REM (SOREM), and HLA results were all considered.
In the presence of appropriate symptoms, an MSLT with
two periods of SOREM was considered diagnostic, but
if other classical symptoms were present, a patient was
considered to have narcolepsy with only one SOREM.
For example, one SOREM would be sufficient if the
symptoms were classical and the patient had clear cata-
plexy. HLA markers were not used as primary diagnos-
tic markers by themselves.
Sodium oxybate is indicated for the treatment of
narcolepsy, but not currently indicated for FM or CFS.
Patients who were found to have a clinical picture and
supportive diagnostic studies that justified the use of
oxybate had this medication recommended. In a minor-
ity of cases, it was deemed sufficient to recommend
oxybate on clinical grounds alone, in keeping with
appropriate clinical practice. When appropriate, if they
had not previously been used, pregabalin12 or duloxet-
ine13,14 were tried first. Most patients with pain had
already tried these medications previously. A smaller
number tried them de novo, and then went on to try
oxybate. Pregabalin or duloxetine were not discontin-
ued if they were still in use. Nearly all patients with CFS
and FM treated in this practice during this time frame
were included in this analysis.
RESULTS
A total of 118 charts were identified for retrospective
review. Twenty-five of the patients were male (21%) and
93 were female (79%). The mean age was 53 1 12 years.
Out of 118 patients, 117 (99%) had long-standing
fatigue and 82 (69%) had generalized pains and muscle
aches in a pattern consistent with FM. Fourteen of 25
male patients (56%) and 68 of 92 female patients (74%)
had pain. The pain was typically described as “all over”
(as characteristic in FM). Detailed results of diagnostic
evaluation in this group have been submitted separately.
The results are briefly summarized below.
Approximately 40% of patients met criteria for clas-
sical narcolepsy, although most of the remainder had
features suggestive of the disorder. Of 92 patients having
MSLT, 73 (80%) patients were abnormal, showing
shortened time to onset of daytime sleep onset, indicat-
ing objective excessive sleepiness. Overall (male and
female combined), 36% had at least one period of
SOREM. Overall, 43% were positive for HLA DQB1-
0602, compared with an 8% average population preva-
lence in 225 population prevalences (P < 0.0001). Sleep
architecture was not graded formally. However, quali-
tatively it was reviewed in all cases, and in nearly every
case there was disrupted sleep, poorly maintained sleep,
and failure to achieve deeper stages of sleep.
Eighty-five of the 118 patients referred for treatment
with oxybate tried at least one dose of the medication.
Of the 85 patients who started oxybate, 37 took it
continuously thereafter with good response, 2 took the
medication with good response but stopped only because
of financial considerations (said they would have stayed
on it otherwise), and 8 started the medication, stopped
briefly for various reasons, and then resumed the medi-
cation. Forty-seven of the 85 (55%) patients were con-
sidered to have had a clear positive, efficacious response
to the medication, based on their choice to stay on
the medication. (Table 1) Altogether, of the 85 patients
taking at least one dose of the medication, 50 patients
(59%) reported substantial relief of pain and 64 (75%)
had significant relief of fatigue. Forty-six (54%) had
simultaneous relief of both fatigue and pain.
Of the remainder, five were either lost to follow up or
gave no reason for discontinuing the medication, and
three stopped because of social issues (related to periods
of deep, unresponsive sleep that the medication causes).
The remaining 30 discontinued therapy due to other
side effects. Note that some patients who have chosen to
restart the medication after completion of this study
analysis are listed among these 30 who discontinued,
rather than among those who restarted. Thus, the listed
number of patients remaining on the medication is a
conservative number.
Adverse effects are tabulated in Tables 2 and 3.
Table 3 lists side effects that patients could accommodate
to, that dissipated, or that otherwise did not prevent
the patients from continuing on the medication. Table 4
includes side effects that improved at higher doses.
No patients exhibited addiction or physical depen-
dence. Although a specific percentage was not tracked,
numerous patients in the practice have stopped the
Table 1. Columns 3 and 4 Include Some Who Later










85 47 (55%) 50 (59%) 64 (75%)
Of all the patients who started on treatment (column 1), the second column
indicates those who remained on treatment. The third and fourth columns
indicate those who had relief of pain and fatigue, but some of those eventually
discontinued treatment because of side effects, resulting in the lower final
number in column 2.
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medication abruptly for short or long periods of time for
various reasons (eg, traveling on vacation or cost issues).
None experienced withdrawal symptoms. Generally,
significant fatigue or pain recurred after 7 to 30 days,
and symptoms gradually returned to baseline in 30 to 90
days. No known cases of abuse occurred.
DISCUSSION
The group of patients clearly had objective hypersomnia
as an important finding. Clinically, the original presen-
tations were typical of CFS or FM. Although disrupted
sleep has been noted in FM, objective hypersomnia
has not clearly been noted in these two groups. This is
important regarding current advances in treatment and
further research for these patients.
Our patients demonstrated a constellation of con-
sistent findings. The distinction between our patients
and CFS or FM is indistinct. When test results were
combined with clinical characteristics, these cases
were better classified as a “narcoleptiform syndrome”
(Table 5). In this syndrome, the fatigue component of
the syndrome follows the description of CFS, and the
pain component follows the usual description of FM.
In addition to hypersomnia, the sleep disorder has
many features of narcolepsy, being entirely classical in
approximately 40% of cases, and having many of the
features in most of the other cases. This provides a
rationale for the use of sodium oxybate.
None of these cases had originally been referred to
the practice for diagnosis or treatment of narcolepsy or
a sleep disorder. Thus, the diagnosis of the sleep disorder
or narcolepsy in every case was unanticipated. Further-
more, as only a minority had been referred for treatment
of FM and very few had been referred for treatment of
fatigue, this study suggests that these disorders are quite
prevalent and often under-diagnosed. This finding is in
keeping with published data, which suggests that FM
and CFS are quite prevalent.
The high response rate to oxybate first and foremost
provides a novel and effective treatment intervention for
this refractory group of patients. The response rate is
very promising compared with previously suggested
therapies, as these patients had generally tried duloxet-
Table 2. Side Effects Occurring in More than One
Patient





Psychiatric/behavioral changes 6 7
Lightheadedness 6 7
Anxiety 6 7
Sleep paralysis 4 5
Numbness, parasthesiae 4 5
Weight loss 4 5




Unmasked sleep apnea 2 2
Polyphagia 2 2















Table 4. Side Effects Improving with Increased Dose:








Table 5. The Narcoleptiform Syndrome: Common
Features Present in These Cases
Long-standing chronic fatigue: either sleepiness or sleep attacks,
neuromuscular weariness or fatigability, or both
Generalized muscular and joint pains, and tender points characteristic
of FM
Other symptoms of CFS or FM such as memory loss, difficulty with
concentration, gastrointestinal disturbances, weight gain, and others
tabulated for CFS and FM
Poor sleep, unrefreshing sleep, excessively light sleep, inability to sustain
sleep
Associated symptoms of narcolepsy such as cataplexy and sleep paralysis
Disrupted sleep on polysomnogram or lack of deep sleep, without other
sleep disorders such as sleep apnea or restless legs syndrome
Excessive daytime sleepiness confirmed by MSLT
Sleep onset REM on MSLT
HLA DQB1-0602 present (in some cases)
The more features that are present, the more typical the case.
CFS, chronic fatigue syndrome; FM, fibromyalgia; HLA, human leukocyte antigen;
MSLT, Multiple Step Latency Test; REM, rapid eye movement.
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ine and pregabalin and failed or achieved an inade-
quate response. These results expand upon some recent
smaller studies, suggesting a role for oxybate in the
treatment of FM and further suggesting a role for
oxybate in the treatment of CFS. By showing that
patients with predominant features of fatigue only (CFS)
also respond, this study points to the need for pro-
spective studies in CFS as well. Since this retrospective
study was submitted, a recent prospective study has
been published which shows similar positive findings
with sodium oxybate.15
The prospective treatment study recently published
does not explore sleep studies or the mechanism of FM.
This study provides new information that adds to the
understanding of the role of oxybate, and provides a
rationale to the use of this medication in FM and CFS.
By showing the response to oxybate in the same group
of patients who have been demonstrated to have abnor-
mal sleep studies, we provide a physiological rationale
for its use and a basis for further study.
The retrospective nature of our study does not allow
us to determine if sleep study testing can be used to
differentiate and predict response to oxybate in CFS and
FM. Our results suggest that this important question
should be addressed with a prospective study. Sleep
studies may also prove useful in better classifying CFS
and FM, for purposes of research into the underlying
pathophysiology and etiologies of these disorders. The
classification of these disorders may be enhanced by
adding sleep studies to their evaluation.
Sodium oxybate produces a high profile of side
effects. There is an initial start-up and titration phase
during which there may be many side effects, and there
are side effects during continuous administration. Some
side effects are related to increasing dosage, but para-
doxically, some side effects are related to inadequate
dosing. Because the medication induces deep sleep, inad-
equate dosing can produce very unpleasant effects. In
addition, some side effects are masked at higher doses
when patients fall asleep. For example, some patients
report reduced nausea at higher doses when they fall
asleep quickly, or reduced episodes of sleep paralysis.
With prolonged use of oxybate, we have observed
tachyphylaxis, or possibly a pseudo-tachyphylaxis.
After 6 months to 2 years, many patients say the medi-
cation “doesn’t work as well as it used to”—either
because depth of sleep is not fully adequate, or time of
sleep is shortened. We believe this may represent the fact
that they are simply no longer so extremely tired, they
have less accumulated sleep debt. Given the study
design, it was not possible to establish correct dosage
requirements for these long-term patients. Retitration
studies are needed. Whether receptor down-regulation
occurs to produce true tachyphylaxis is not known
and merits further study. Beneficial responses in some
patients may require higher doses than current short-
term studies suggest.
For many years, the poor nighttime sleep in FM has
been ascribed to the pain. In narcolepsy, the poor night-
time sleep is now recognized as a primary component
of the disease itself. The mechanism of action of oxybate
is to induce deep sleep. The high response rate in our
patients matches the sleep study results, which suggests
that a primary narcoleptiform process is present in this
group of patients. Thus, the treatment results support
the hypothesis that disrupted sleep is part of the primary
mechanism and cause of the fatigue and pain, rather
than secondary to the pain.
Although sleep onset REM has been considered
important for the diagnosis of narcolepsy, effective
treatment with oxybate restores deep stages 3 and 4
sleep, not REM. In these cases that we have identified
without SOREM that respond to oxybate, the implica-
tion may be that CFS and FM are more related to
deficiencies of deep sleep. Thus, the short MSLTs may be
more significant diagnostically and pathophysiologically
than the presence or absence of SOREM. This also
merits further study.
Patients with CFS, and with chronic generalized pain
suggestive of FM, have approximately the same abnor-
mal rate of excessive daytime sleepiness demonstrated
by standardized sleep testing. A significant but similar
subset has features suggesting narcoleptic characteris-
tics. Approximately the same response to sodium
oxybate occurs with pain and fatigue. Treatment aimed
at disrupted sleep seems to be an equally appropriate
approach for either diagnosis and fits with our proposed
classification as a narcoleptiform syndrome.
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